StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.65+0.06 (+1.67%)

Close on Nov 17, 2026Market cap $362.98MP/E –Yield –

ARS Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ARS Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $116.93M, up 4.1% year over year. For fiscal 2025 it was $84.28M, down 5.5% from the year before. The highest annual figure on record is $89.15M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$84.28M-5.5%
FY2024Dec 31, 2024$89.15M+297063.3%
FY2023Dec 31, 2023$30.00K-97.7%
FY2022Dec 31, 2022$1.32M-76.1%
FY2021Dec 31, 2021$5.51M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.66M+114.2%
Q1 FY2026Mar 31, 2026$22.68M+184.5%
Q4 FY2025Dec 31, 2025$28.09M-67.6%
Q3 FY2025Sep 30, 2025$32.50M+1471.6%
Q2 FY2025Jun 30, 2025$15.72M+3043.4%
Q1 FY2025Mar 31, 2025$7.97M–
Q4 FY2024Dec 31, 2024$86.58M–
Q3 FY2024Sep 30, 2024$2.07M–
Q2 FY2024Jun 30, 2024$500.00K+4900.0%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$10.00K-97.8%
Q1 FY2023Mar 31, 2023$20.00K-97.0%
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$189.00K–
Q2 FY2022Jun 30, 2022$464.00K–
Q1 FY2022Mar 31, 2022$663.00K–

More ARS Pharmaceuticals figures

See a number that looks wrong?